Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 13/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3262979 | 0.79 | NR3C2 (0.47) | NR3C2MMP12NR3C1PARP1ALDH1A1 | |
| SCHEMBL655255 | 0.79 | NR3C2 (0.47) | NR3C2MMP12NR3C1PARP1ALDH1A1 | |
| SCHEMBL21400859 | 0.79 | NR3C2 (0.47) | NR3C2MMP12NR3C1PARP1ALDH1A1 | |
| SCHEMBL5367006 | 0.79 | NR3C2 (0.47) | NR3C2MMP12NR3C1PARP1ALDH1A1 | |
| SCHEMBL592791 | 0.79 | NR3C2 (0.47) | NR3C2MMP12NR3C1PARP1ALDH1A1 | |
| SCHEMBL4343340 | 0.79 | NR3C2 (0.47) | NR3C2MMP12NR3C1PARP1ALDH1A1 | |
| SCHEMBL29712026 | 0.79 | NR3C2 (0.47) | NR3C2MMP12NR3C1PARP1ALDH1A1 | |
| SCHEMBL12235340 | 0.79 | PARP1 (0.50) | NR3C2MMP12NR3C1PARP1 | |
| SCHEMBL12212772 | 0.79 | NR3C2 (0.47) | NR3C2MMP12NR3C1PARP1ALDH1A1 | |
| SCHEMBL15979035 | 0.79 | KCNH2 (0.48) | NR3C2MMP12ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-11-16 | — | — | US | disclosed |
| EP-3458452-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2021070132-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | Bugworks Research, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-07 | — | — | US | disclosed |
| EP-3639824-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-04-22 | — | — | EP | disclosed |
| EP-3182973-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| WO-2017199265-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RESEARCH INDIA PVT LTD (IN) | 2017-11-23 | — | — | WO | disclosed |
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| US-6900232-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-6855722-B2 | Substituted indoles and their use as integrin antagonists | DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040259869-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2004-12-23 | — | — | US | disclosed |
| US-20040171620-A1 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-09-02 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20040043988-A1 | Cycloalkyl alkanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | disclosed |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171620-A1 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | NRDC, NUCB2, NDC1 | NR3C2 2370/4885MMP12 2500/4885NR3C1 1878/4885 |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | DHPS, HSD17B11, GNE | NR3C2 791/4885MMP12 3345/4885NR3C1 1384/4885 |
| US-20040043988-A1 | Cycloalkyl alkanoic acids as intergrin receptor antagonists | ADGRE5, ITGA5, ADGRF1 | NR3C2 514/4885MMP12 1987/4885NR3C1 505/4885 |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | NR3C2 681/4885MMP12 1936/4885NR3C1 945/4885 |
| US-20040259869-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | ITGA5, ITGB5, ITGB3 | NR3C2 821/4885MMP12 1532/4885NR3C1 1069/4885 |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGAL, ITGA5 | NR3C2 342/4885MMP12 637/4885NR3C1 471/4885 |
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | CYP3A7, UGT2B7, SFPQ | NR3C2 722/4885MMP12 4524/4885NR3C1 3995/4885 |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | ITGA5, ITGB5, ITGB3 | NR3C2 821/4885MMP12 1532/4885NR3C1 1069/4885 |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | ALPI, HLA-A, HLA-B | NR3C2 2377/4885MMP12 624/4885NR3C1 3666/4885 |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | NR3C2 2869/4885MMP12 2366/4885NR3C1 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.